My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

182.13 +1.38 (+0.76%)

Streaming Delayed Price Updated: 12:06 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

Biogen (BIIB) Stock Trades Down, Here Is Why

July 21, 2025

Shares of biotech company Biogen (NASDAQ:BIIB) fell 3.1% in the morning session after analysts at Truist downgraded the stock, citing concerns over the company's growth prospects and high-risk...

Via StockStory

Topics Lawsuit

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing ↗

July 21, 2025

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage clinical pipeline support.

Via Benzinga

What's going on in today's session: S&P500 movers ↗

July 21, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

What Does the Market Think About Biogen? ↗

June 17, 2025

Via Benzinga

Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary

July 21, 2025

From Biogen Inc.

Via GlobeNewswire

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit

Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? ↗

July 14, 2025

BofA cuts Bristol Myers' 2025 EPS and sales estimates slightly and flags medium-term pressure from generics, while maintaining a Neutral rating.

Via Benzinga

3 Low-Volatility Stocks in Hot Water

July 11, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025

From Stoke Therapeutics, Inc.

Via Business Wire

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025

From Biogen Inc.

Via GlobeNewswire

What's Driving the Market Sentiment Around Biogen? ↗

July 09, 2025

Via Benzinga

Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit ↗

July 07, 2025

The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share.

Via Stocktwits

1 Value Stock with Exciting Potential and 2 to Approach with Caution

July 03, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

June 30, 2025

From Biogen Inc.

Via GlobeNewswire

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

June 27, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗

June 25, 2025

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Via Benzinga

Nvidia To Rally Around 69%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

June 25, 2025

Via Benzinga

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

June 25, 2025

From Biogen Inc.

Via GlobeNewswire

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms ↗

June 22, 2025

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Via Stocktwits

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

June 18, 2025

From Biogen Inc.

Via GlobeNewswire

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics ↗

June 16, 2025

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Via Stocktwits

Topics Government

Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal ↗

June 16, 2025

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies by expanding its CNS portfolio.

Via Benzinga

Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million ↗

June 16, 2025

The deal expands Supernus Pharmaceuticals' presence in the nonpsychiatric space.

Via Investor's Business Daily

Topics ETFs

1 Profitable Stock with Exciting Potential and 2 to Avoid

June 13, 2025

A company with profits isn’t always a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Via StockStory

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗

June 12, 2025

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

Via Benzinga

Demystifying Biogen: Insights From 11 Analyst Reviews ↗

June 12, 2025

Via Benzinga

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity

June 12, 2025

From Biogen Inc.

Via GlobeNewswire

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 03, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

May 29, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen...

Via StockStory

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.